<s> The University of Toronto stepped deeper into the contest for Connaught BioSciences Inc. by reaching an unusual agreement with Ciba-Geigy Ltd. and Chiron Corp . </s>
<s> The University said the two companies agreed to spend 25 million Canadian dollars -LRB- $ 21.3 million -RRB- over 10 years on research at Canadian universities if they are successful in acquiring the vaccine maker . </s>
<s> It said $ 10 million would go to the University of Toronto . </s>
<s> Ciba-Geigy and Chiron have made a joint bid of C$ 866 million for Connaught , and Institut Merieux S.A. of France has made a rival bid of C$ 942 million . </s>
<s> The University is seeking an injunction against the Merieux bid , arguing that Connaught 's predecessor company agreed in 1972 that Connaught 's ownership would n't be transferred to foreigners . </s>
<s> The university implied that it would drop its opposition to foreign ownership if Ciba-Geigy and Chiron are successful with their lower bid . </s>
<s> It said the new agreement would `` replace '' the old one that forms the basis of its suit against the Merieux takeover . </s>
<s> `` Notwithstanding foreign ownership of Connaught , this accord would enhance research and development in Canada , '' said James Keffer , the university 's vice president of research . </s>
<s> Ciba-Geigy is a Swiss pharmaceutical company and Chiron is based in Emeryville , Calif . </s>
<s> In a statement , Jacques-Francois Martin , director general of Merieux , said the French company is still determined to acquire Connaught . </s>
<s> While he did n't comment directly on the pact between Ciba-Geigy and the university , he said Merieux can transfer new products and technologies to Connaught more rapidly than other companies `` not currently producing and marketing vaccines -LCB- who -RCB- can only promise this for some ... years in the future . '' </s>
<s> In national over-the-counter trading yesterday , Connaught closed at $ 28.625 , up $ 1.25 . </s>
